Human breast cancer in the athymic nude mouse: Cysto antiestrogen therapy

European Journal of Cancer & Clinical Oncology 23, 1189-1196 DOI: 10.1016/0277-5379(87)90154-4

Citation Report

#	Article	IF	CITATIONS
1	Endocrine therapy of human breast cancer grown in nude mice. Breast Cancer Research and Treatment, 1987, 10, 229-242.	2.5	15
2	The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole. Breast Cancer Research and Treatment, 1988, 11, 197-209.	2.5	122
3	The clinical biology of hormone-responsive breast cancer. Cancer Treatment Reviews, 1988, 15, 33-51.	7.7	15
4	Micronutrient and Lipid Interactions in Cancera. Annals of the New York Academy of Sciences, 1990, 587, 78-91.	3.8	11
5	Long-term adjuvant tamoxifen therapy for breast cancer. Breast Cancer Research and Treatment, 1990, 15, 125-136.	2.5	112
6	Sensitivity and insensitivity of breast cancer to tamoxifen. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 765-770.	2.5	18
7	3 Mechanisms of growth regulation of human breast cancer. Bailliere's Clinical Endocrinology and Metabolism, 1990, 4, 51-66.	1.0	4
8	Long-term adjuvant tamoxifen therapy for breast cancer: The prelude to prevention. Cancer Treatment Reviews, 1990, 17, 15-36.	7.7	16
9	Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids. Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 305-316.	2.5	99
10	Tamoxifen in premenopausal patients with metastatic breast cancer: a review Journal of Clinical Oncology, 1991, 9, 1283-1297.	1.6	119
11	Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER Molecular Endocrinology, 1992, 6, 2167-2174.	3.7	50
12	Tamoxifen and the isomers of 4-hydroxytamoxifen in tamoxifen-resistant tumors from breast cancer patients Journal of Clinical Oncology, 1992, 10, 304-310.	1.6	130
13	The role of tamoxifen in the treatment and prevention of breast cancer. Current Problems in Cancer, 1992, 16, 134-176.	2.0	84
14	Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Research and Treatment, 1992, 24, 85-95.	2.5	670
15	The future of new pure antiestrogens in clinical breast cancer. Breast Cancer Research and Treatment, 1993, 25, 1-9.	2.5	133
16	Drug resistance to tamoxifen during breast cancer therapy. Breast Cancer Research and Treatment, 1993, 27, 27-40.	2.5	41
17	Mechanisms of hormone resistance in breast cancer. Breast Cancer Research and Treatment, 1993, 26, 119-130.	2.5	66
18	A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens. Breast Cancer Research and Treatment, 1993, 26, 139-147.	2.5	27

#	Article	IF	CITATIONS
19	Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Research and Treatment, 1993, 24, 227-239.	2.5	58
20	Tamoxifen resistance in breast cancer. Critical Reviews in Oncology/Hematology, 1993, 14, 173-188.	4.4	49
21	Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. European Journal of Cancer, 1993, 29, 2256-2264.	2.8	88
22	Are breast tumours resistant to tamoxifen also resistant to pure antioestrogens?. Journal of Steroid Biochemistry and Molecular Biology, 1993, 47, 107-114.	2.5	24
23	Can Hormone "Resistant" Breast Cancer Cells Be Inappropriately Stimulated by Tamoxifen?. Annals of the New York Academy of Sciences, 1993, 684, 63-74.	3.8	5
24	A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 3383-3387.	7.1	78
25	Mechanisms of tamoxifen resistance. Breast Cancer Research and Treatment, 1994, 32, 49-55.	2.5	121
26	Flow cytometry: Potential utility in monitoring drug effects in breast cancer. Breast Cancer Research and Treatment, 1994, 32, 57-65.	2.5	12
27	Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Research and Treatment, 1994, 31, 41-52.	2.5	110
28	Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Research and Treatment, 1994, 31, 117-127.	2.5	68
29	The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Research and Treatment, 1994, 31, 129-138.	2.5	144
30	Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast-cancer cells. International Journal of Cancer, 1994, 56, 295-300.	5.1	66
31	Tamoxifen withdrawal responses $\hat{a} \in$ " chance observations or clinical clues to antioestrogen resistance?. Breast, 1994, 3, 199-201.	2.2	7
32	Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance. Cancer Chemotherapy and Pharmacology, 1994, 35, 149-152.	2.3	3
33	The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemotherapy and Pharmacology, 1994, 34, 89-95.	2.3	126
34	The antioxidant action of a pure antioestrogen: Ability to inhibit lipid peroxidation compared to tamoxifen and 17β-oestradiol and relevance to its anticancer potential. Biochemical Pharmacology, 1994, 47, 493-498.	4.4	27
35	How do breast cancers become hormone resistant?. Journal of Steroid Biochemistry and Molecular Biology, 1994, 49, 295-302.	2.5	30
36	?Studies on the estrogen receptor in breast cancer? ? 20 years as a target for the treatment and prevention of cancer. Breast Cancer Research and Treatment, 1995, 36, 267-285.	2.5	140

#	ARTICLE	IF	CITATIONS
37	The decreased influence of overall treatment time on the response of human breast tumor xenografts following prolongation of the potential doubling time (Tpot). International Journal of Radiation Oncology Biology Physics, 1995, 31, 833-840.	0.8	16
38	Tamoxifen metabolism as a mechanism for resistance. Endocrine-Related Cancer, 1995, 2, 53-58.	3.1	4
39	In vitro development of tamoxifen resistance. Endocrine-Related Cancer, 1995, 2, 37-44.	3.1	3
40	A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog Molecular Endocrinology, 1995, 9, 1053-1063.	3.7	58
41	Cross-resistance and molecular mechanisms in antiestrogen resistance. Endocrine-Related Cancer, 1995, 2, 59-72.	3.1	16
42	Tamoxifen: Toxicities and Drug Resistance During the Treatment and Prevention of Breast Cancer. Annual Review of Pharmacology and Toxicology, 1995, 35, 195-211.	9.4	111
43	Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen-Sensitive and-Resistant Experimental and Clinical Breast Cancer. Annals of the New York Academy of Sciences, 1995, 761, 148-163.	3.8	83
44	The biological action of cDNAs from mutated estrogen receptors transfected into breast cancer cells. Cancer Letters, 1995, 90, 35-42.	7.2	11
45	Response-specific antiestrogen resistance in a newly characterized MCF-7 human breast cancer cell line resulting from long-term exposure to trans-hydroxytamoxifen. Journal of Steroid Biochemistry and Molecular Biology, 1996, 59, 121-134.	2.5	57
46	Pure Antiestrogens The Most Important Advance in the Endocrine Therapy of Breast Cancer since 1896?. Annals of the New York Academy of Sciences, 1996, 784, 325-335.	3.8	10
47	Mechanisms of Tamoxifen Resistance in the Treatment of Advanced Breast Cancer. Acta Oncológica, 1996, 35, 9-14.	1.8	30
48	Animal models of breast cancer: Their diversity and role in biomedical research. Breast Cancer Research and Treatment, 1996, 39, 1-6.	2.5	55
49	Human breast cancer cell line xenografts as models of breast cancer — The immunobiologies of recipient mice and the characteristics of several tumorigenic cell lines. Breast Cancer Research and Treatment, 1996, 39, 69-86.	2.5	114
50	Athymic nude mouse model for the study of new antioestrogens in breast cancer. Breast, 1996, 5, 181-185.	2.2	4
51	Angiogenic response of MCF7 human breast cancer to hormonal treatment: Assessment by dynamic GdDTPA-enhanced MRI at high spatial resolution. Journal of Magnetic Resonance Imaging, 1996, 6, 195-202.	3.4	23
52	Oestrogens, Beatson and endocrine therapy. Endocrine-Related Cancer, 1997, 4, 371-380.	3.1	15
53	The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. Journal of Steroid Biochemistry and Molecular Biology, 1997, 62, 119-128.	2.5	32
54	Molecular mechanisms and future uses of antiestrogens. Molecular Aspects of Medicine, 1997, 18, 167-247.	6.4	12

#	Article	IF	CITATIONS
55	Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials Group Journal of Clinical Oncology, 1997, 15, 3141-3148.	1.6	28
56	Solid-phase extraction and high-performance liquid chromatographic determination of tamoxifen and its major metabolites in breast tumour tissues. Biomedical Applications, 1997, 698, 269-275.	1.7	21
57	Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy. Cancer, 1998, 82, 395-402.	4.1	258
58	Understanding the antiestrogenic actions of raloxifene and a mechanism of drug resistance to tamoxifen. Breast Cancer, 1998, 5, 99-106.	2.9	9
59	Hormonal therapy of breast cancer. Cancer Treatment Reviews, 1998, 24, 221-240.	7.7	50
60	Tamoxifen in the Treatment of Breast Cancer. New England Journal of Medicine, 1998, 339, 1609-1618.	27.0	1,156
61	Mechanisms of Action of Antiestrogens: Relevance to Clinical Benefits and Risks. Cancer Investigation, 1998, 16, 604-611.	1.3	26
62	Role of proliferation and apoptosis in net growth rates of human breast cancer cells (MCF-7) treated with oestradiol and/or tamoxifen. Cell Proliferation, 1999, 32, 289-302.	5.3	30
63	Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts. , 1999, 81, 309-313.		30
64	Current status of tamoxifen use: An update for the surgical oncologist. , 1999, 72, 42-49.		13
65	Influence of Antiestrogens on the Invasiveness and Laminin Attachment of Breast Cancer Cells. Cancer Investigation, 1999, 17, 10-18.	1.3	7
66	EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and end endometrium. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 51-84.	2.5	157
67	Altering the Estrogenic Milieu of Breast Cancer with a Focus on the New Aromatase Inhibitors. Pharmacotherapy, 2000, 20, 280-291.	2.6	2
68	True. British Journal of Cancer, 2000, 82, 1629-1635.	6.4	52
69	Development and characterization of a tamoxifen-resistant breast carcinoma xenograft. British Journal of Cancer, 2000, 82, 1844-1850.	6.4	19
70	How Is Tamoxifen's Action Subverted?. Journal of the National Cancer Institute, 2000, 92, 92-94.	6.3	9
71	Interconnections between E2-Dependent Regulation of Cell Cycle Progression and Apoptosis in MCF-7 Tumors Growing on Nude Mice. Experimental Cell Research, 2000, 254, 241-248.	2.6	18
72	New Generation Aromatase Inhibitors in Breast Cancer. Pharmacoeconomics, 2000, 17, 121-132.	3.3	8

#	Article	IF	CITATIONS
73	Comparative Tolerability of First-Generation Selective Estrogen Receptor Modulators in Breast Cancer Treatment and Prevention. Drug Safety, 2001, 24, 1039-1053.	3.2	12
74	Control of the estrogen-like actions of the tamoxifen–estrogen receptor complex by the surface amino acid at position 351. Journal of Steroid Biochemistry and Molecular Biology, 2001, 76, 61-70.	2.5	40
75	Molecular and pharmacological aspects of antiestrogen resistance. Journal of Steroid Biochemistry and Molecular Biology, 2001, 76, 71-84.	2.5	125
76	Pure Antiestrogens and Breast Cancer. Current Medical Research and Opinion, 2001, 17, 282-289.	1.9	20
77	Chemoprevention with Antiestrogens: The Beginning of the End for Breast Cancer. Annals of the New York Academy of Sciences, 2001, 952, 60-72.	3.8	6
78	Endocrine therapy in the treatment of metastatic breast cancer. Seminars in Oncology, 2001, 28, 291-304.	2.2	86
79	Selective Estrogen Receptor Modulation: The Search for an Ideal Hormonal Therapy for Breast Cancer. Cancer Investigation, 2001, 19, 649-659.	1.3	38
80	Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. Advances in Protein Chemistry, 2001, 56, 293-368.	4.4	18
81	Magnolol suppresses proliferation of cultured human colon and liver cancer cells by inhibiting DNA synthesis and activating apoptosis. Journal of Cellular Biochemistry, 2002, 84, 532-544.	2.6	101
82	Changing role of the oestrogen receptor in the life and death of breast cancer cells. Breast, 2003, 12, 432-441.	2.2	24
83	Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene, 2003, 22, 7316-7339.	5.9	421
84	Tamoxifen: a most unlikely pioneering medicine. Nature Reviews Drug Discovery, 2003, 2, 205-213.	46.4	676
85	New paradigms in adjuvant systemic therapy of breast cancer Endocrine-Related Cancer, 2003, 10, 75-89.	3.1	3
86	Paradoxical Action of Fulvestrant in Estradiol-Induced Regression of Tamoxifen-Stimulated Breast Cancer. Journal of the National Cancer Institute, 2003, 95, 1597-1608.	6.3	121
87	New approaches to the understanding of tamoxifen action and resistance Endocrine-Related Cancer, 2003, 10, 267-277.	3.1	45
88	Dominant-Negative Nuclear Receptor Corepressor Relieves Transcriptional Inhibition of Retinoic Acid Receptor but Does Not Alter the Agonist/Antagonist Activities of the Tamoxifen-Bound Estrogen Receptor. Molecular Endocrinology, 2003, 17, 1543-1554.	3.7	14
89	Long-Term Exposure to Tamoxifen Induces Hypersensitivity to Estradiol. Clinical Cancer Research, 2004, 10, 1530-1534.	7.0	51
90	Raloxifene Rebound Regression. Cancer Investigation, 2004, 22, 718-722.	1.3	5

#	ARTICLE Models of Hormone Resistance In Vitro and In Vivo 2006, 120, 453-464	IF	CITATIONS
92	Upregulation of PKC-δ contributes to antiestrogen resistance in mammary tumor cells. Oncogene, 2005, 24, 3166-3176.	5.9	79
93	Naloxone acts as an antagonist of estrogen receptor activity in MCF-7 cells. Molecular Cancer Therapeutics, 2006, 5, 611-620.	4.1	53
95	Controversies in adjuvant endocrine therapy for pre- and post-menopausal women with breast cancer. European Journal of Cancer, Supplement, 2008, 6, 4-9.	2.2	9
96	Effects of Fungal-derived High Molecular Weight Chitosan on 5-Fluorouracil-induced Adverse Reactions. Journal of Bioactive and Compatible Polymers, 2008, 23, 458-472.	2.1	5
97	Evaluation of Multi-Target and Single-Target Liposomal Drugs for the Treatment of Gastric Cancer. Bioscience, Biotechnology and Biochemistry, 2008, 72, 1586-1594.	1.3	22
98	Advances in Adjuvant Endocrine Therapy for Postmenopausal Women. Journal of Clinical Oncology, 2008, 26, 798-805.	1.6	112
99	Tamoxifen inhibits transforming growth factor-α gene expression in human breast carcinoma samples treated with triiodothyronine. Journal of Endocrinological Investigation, 2008, 31, 1047-1051.	3.3	20
100	The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer—Survival or Death?. Journal of Clinical Oncology, 2008, 26, 3073-3082.	1.6	98
101	<i>In vitro</i> and <i>in vivo</i> study of phloretinâ€induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter. International Journal of Cancer, 2009, 124, 2210-2219.	5.1	129
102	Inhibitory effects of chitooligosaccharides on tumor growth and metastasis. Food and Chemical Toxicology, 2009, 47, 1864-1871.	3.6	185
103	Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2009, 114, 8-20.	2.5	73
104	The St. Gallen Prize Lecture 2011: Evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. Breast, 2011, 20, S1-S11.	2.2	23
105	Arsenic trioxide induces autophagy and apoptosis in human glioma cells in vitro and in vivo through downregulation of survivin. Journal of Molecular Medicine, 2011, 89, 927-941.	3.9	64
106	Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18879-18886.	7.1	151
107	Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations. Hormone Molecular Biology and Clinical Investigation, 2012, 9, 143-163.	0.7	62
108	Arsenic Trioxide Enhances the Radiation Sensitivity of Androgen-Dependent and -Independent Human Prostate Cancer Cells. PLoS ONE, 2012, 7, e31579.	2.5	41
109	Estrogen Receptor-α Variant, ER-α36, is Involved in Tamoxifen Resistance and Estrogen Hypersensitivity. Endocrinology, 2013, 154, 1990-1998.	2.8	49

#	Article	IF	CITATIONS
110	Estrogen-Mediated Mechanisms to Control the Growth and Apoptosis of Breast Cancer Cells. Vitamins and Hormones, 2013, 93, 1-49.	1.7	13
111	Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause, 2013, 20, 372-382.	2.0	34
112	Linking Estrogen-Induced Apoptosis With Decreases in Mortality Following Long-term Adjuvant Tamoxifen Therapy. Journal of the National Cancer Institute, 2014, 106, dju296-dju296.	6.3	34
113	Auricularia polytricha polysaccharides induce cell cycle arrest and apoptosis in human lung cancer A549 cells. International Journal of Biological Macromolecules, 2014, 68, 67-71.	7.5	61
114	Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death. British Journal of Cancer, 2014, 110, 1488-1496.	6.4	22
115	Defining the Conformation of the Estrogen Receptor Complex That Controls Estrogen-Induced Apoptosis in Breast Cancer. Molecular Pharmacology, 2014, 85, 789-799.	2.3	24
116	Selective estrogen-induced apoptosis in breast cancer. Steroids, 2014, 90, 60-70.	1.8	11
117	Breast Cancer Cell Apoptosis with Phytoestrogens Is Dependent on an Estrogen-Deprived State. Cancer Prevention Research, 2014, 7, 939-949.	1.5	48
118	Long-term exposure to dietary sources of genistein induces estrogen-independence in the human breast cancer (MCF-7) xenograft model. Molecular Nutrition and Food Research, 2015, 59, 413-423.	3.3	27
119	The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocrine-Related Cancer, 2015, 22, R1-R31.	3.1	111
120	MCF-7 CellsChanging the Course of Breast Cancer Research and Care for 45 Years. Journal of the National Cancer Institute, 2015, 107, djv073-djv073.	6.3	189
121	Estrogen Receptor Mutations Found in Breast Cancer Metastases Integrated With the Molecular Pharmacology of Selective ER Modulators. Journal of the National Cancer Institute, 2015, 107, djv075.	6.3	35
122	Roles of the ER-α36-EGFR/HER2 positive regulatory loops in tamoxifen resistance. Steroids, 2016, 111, 95-99.	1.8	16
123	Construction of highly stable selenium nanoparticles embedded in hollow nanofibers of polysaccharide and their antitumor activities. Nano Research, 2017, 10, 3775-3789.	10.4	45
124	Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death and Disease, 2018, 9, 21.	6.3	16
125	A unifying biology of sex steroid-induced apoptosis in prostate and breast cancers. Endocrine-Related Cancer, 2018, 25, R83-R113.	3.1	21
126	The First Targeted Therapy to Treat Cancer: The Tamoxifen Tale. Cancer Drug Discovery and Development, 2019, , 151-188.	0.4	1
127	Molecular Mechanism for Breast Cancer Incidence in the Women's Health Initiative. Cancer Prevention Research, 2020, 13, 807-816.	1.5	17

#	Article	IF	CITATIONS
128	Development in efficacy assessment in relevant oncology models for breast cancer nanomedicine. , 2020, , 299-329.		2
129	A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice. Science Translational Medicine, 2021, 13, .	12.4	20
130	Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team. Breast Cancer Research and Treatment, 2021, 190, 19-38.	2.5	6
131	NSG-Pro mouse model for uncovering resistance mechanisms and unique vulnerabilities in human luminal breast cancers. Science Advances, 2021, 7, eabc8145.	10.3	10
132	Acquisition of an Antiestrogen-Resistant Phenotype in Breast Cancer: Role of Cellular and Molecular Mechanisms. Cancer Treatment and Research, 1996, 87, 263-283.	0.5	15
133	Possible Mechanisms through which Dietary Lipids, Calorie Restriction, and Exercise Modulate Breast Cancer. Advances in Experimental Medicine and Biology, 1992, 322, 185-201.	1.6	8
134	Estrogen Action and Breast Cancer. , 2004, , 317-358.		1
135	Molecular Biology of the Estrogen Receptor Aids in the Understanding of Tamoxifen Resistance and Breast Cancer Prevention with Raloxifene. Recent Results in Cancer Research, 1998, 152, 265-276.	1.8	6
136	A Laboratory Model To Explain the Survival Advantage Observed in Patients Taking Adjuvant Tamoxifen Therapy. Recent Results in Cancer Research, 1993, 127, 23-33.	1.8	71
137	Monascuspiloin Enhances the Radiation Sensitivity of Human Prostate Cancer Cells by Stimulating Endoplasmic Reticulum Stress and Inducing Autophagy. PLoS ONE, 2012, 7, e40462.	2.5	45
138	Questions about Tamoxifen and the Future Use of Antiestrogens. Oncologist, 1998, 3, 104-110.	3.7	13
139	The β-glucan from <i>Lentinus edodes</i> suppresses cell proliferation and promotes apoptosis in estrogen receptor positive breast cancers. Oncotarget, 2017, 8, 86693-86709.	1.8	48
140	Molecular mechanisms of denbinobin-induced anti-tumorigenesis effect in colon cancer cells. World Journal of Gastroenterology, 2005, 11, 3040.	3.3	30
142	Pharmacology, biology and clinical use of triphenylethylenes. , 2002, , 33-44.		0
143	Recent Progress in Breast Cancer Research. , 2009, , 385-408.		2
144	Clinical Utility of New Antiestrogens. , 2009, , 195-212.		0
145	Acquired Resistance to Tamoxifen: Back to the Beginning. Milestones in Drug Therapy, 2013, , 143-163.	0.1	0
146	Adjuvant Therapy: The Breakthrough. Milestones in Drug Therapy, 2013, , 69-84.	0.1	1

#	Article	lF	CITATIONS
147	Long-Term Tamoxifen Therapy: An Appropriate Chemosuppressive Treatment for Breast Cancer. , 1990, , 43-47.		0
148	The Role of Prolonged Antihormonal Treatment of Breast Cancer: A Strategy for Adjuvant Therapy. , 1991, , 163-183.		0
149	Design of Novel Anti-Endocrine Agents. , 1992, , 47-62.		0
150	Interactions Between Growth Factors and Oestrogens in Breast Cancer Cells. , 1993, , 385-389.		0
151	Why are Steroid Receptor Antagonists Sometimes Agonists?. , 1994, , 357-375.		0
152	Hormone â€~resistance' in breast cancer: The role of normal and mutant steroid receptors. Cancer Treatment and Research, 1994, 71, 111-127.	0.5	1
153	Pure Antioestrogens — A New Horizon in Breast Cancer Therapy?. , 1994, , 55-60.		0
154	Molecular, Cellular, and Systemic Mechanisms of Antiestrogen Action. , 1996, , 307-355.		0
155	Mechanisms of Resistance to Antiestrogens and Their Implications for Crossresistance. , 1996, , 93-122.		0
156	Antiestrogen Resistance in Human Breast Cancer. , 1997, , 115-160.		0
157	Antiestrogen Resistance in Human Breast Cancer. , 1997, , 115-160.		0
158	Understanding the New Biology of Estrogen-Induced Apoptosis and Its Application in Patient Care. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 101-114.	0.1	0
159	The good, the bad and the ugly of tamoxifen at Wisconsin. , 2022, , 83-104.		0
160	Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer. Journal of Medicinal Chemistry, 2022, 65, 3894-3912.	6.4	5
161	Evolution of 3-(4-hydroxyphenyl)indoline-2-one as a scaffold for potent and selective anticancer activity. RSC Medicinal Chemistry, 2022, 13, 711-725.	3.9	1
162	Breast Cancer and Prolactin $\hat{a} \in$ New Mechanisms and Models. Endocrinology, 2022, 163, .	2.8	8